Davos BioSciences

Davos BioSciences AG (DBS) is a non-profit spin-off from CK-CARE and supports pharmaceutical companies in the development of drugs. DBS also operates CK-CARE's biobank, and is certified for this activity by the Swiss Biobanking Platform and can draw on the extensive data and samples for projects with the research-based pharmaceutical industry. Thus, key questions in every phase of preclinical and clinical drug development, development, validation and regulatory qualification of diagnostic tests as well as in clinical trials can be answered quickly and flexibly. Currently, the main expertise is in the field of atopic dermatitis and other allergic diseases and disorders of the immune system.

DBS offers expertise in biobank management, laboratory services and contract research projects. It supports pharmaceutical companies in their efforts to discover and develop therapeutic approaches and biomarkers, and validates new biomarkers and drugs as part of the approval process. Since its inception in 2019, DBS has fully completed three projects, three projects are in progress, and one new project is contracted. There are 2369 (as of Dec. 2022) patients in the CK-CARE biobank managed by DBS, of which skin swabs are available from 97%, blood from 85%, and skin biopsies from 16%.

All proceeds from DBS are reinvested in CK-CARE's research activities.